| 2024-05-03 | +0.56 % |
|
| 2024-05-02 | +3.56 % |
- The article summarizes Organon & Co. (OGN) first quarter 2024 financial results, reporting an increase in revenue of 5% on an as-reported basis and 7% at constant currency, with diluted earnings per share of $0.78 and non-GAAP Adjusted diluted earnings per share of $1.22, leading to a 3.56% increase in stock value due to strong performance in Women’s Health, Biosimilars, and Established Brands franchises, solid profitability, affirmed full year 2024 financial guidance, and the declaration of a quarterly dividend.
- The article is about Organon & Co. (OGN) stock being up by 3.56% last night, and the stock rose due to the company's strong performance in the first quarter of 2024, particularly in areas such as Women's Health, Biosimilars, and Established Brands.
- Organon & Co. (OGN) stock was up by 3.56% last night following a strong first-quarter performance showing revenue growth, particularly in the women's health, biosimilars, and established brands segments; this growth was supported by the company's commitment to achieving its financial targets, disciplined operating expenses, expanding product portfolio, and strategic focus. The stock's rise can also be attributed to its financial metrics, such as a low price-to-earnings ratio and high shareholder yield, indicating future potential, alongside positive outlook and growth predictions from analysts.
|
| 2024-04-29 | +1.89 % |
|
| 2024-04-26 | +0.71 % |
|
| 2024-04-25 | -1.55 % |
|
| 2024-04-23 | +2.89 % |
|
| 2024-04-11 | +0.66 % |
|
| 2024-04-08 | +1.68 % |
|
| 2024-03-26 | +1.68 % |
|
| 2024-03-20 | +1.17 % |
|
| 2024-03-15 | -0.44 % |
|
| 2024-02-28 | -1.16 % |
|
| 2024-02-27 | +2.21 % |
|
| 2024-02-20 | -1.18 % |
|
| 2024-02-16 | +0.48 % |
|
| 2024-02-15 | +13.81 % |
|
| 2024-02-07 | -4.13 % |
|
| 2024-02-01 | +3.54 % |
|
| 2024-01-25 | +2.56 % |
|
| 2024-01-10 | +6.17 % |
|
| 2024-01-08 | +13.12 % |
|
| 2023-12-21 | +3.5 % |
|
| 2023-12-18 | +0.31 % |
|
| 2023-11-21 | -1.43 % |
|
